Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Ampol Profit Surges as Refining Margins Hit Record Highs 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Nvidia Options Price in $280 Billion Earnings Swing 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Tesla Raises Cybertruck Prices by $5,000 in US 
Add as a preferred source on Google
LYON, France, May 2, 2018 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the first quarter ended March 31, 2018, after the close of the financial markets on Monday, May 14, 2018.
An accompanying conference call will be conducted by Philippe Chauveau, Chairman of the Board; Marc Oczachowski, Chief Executive Officer; and François Dietsch, Chief Financial Officer, to review the results. The call will be held at 8:30 AM ET, on Tuesday, May 15, 2018. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Call & Webcast
Tuesday, May 15, 2018 @ 8:30am Eastern Time
Domestic: 866-548-4713
International 323-794-2093
Passcode: 9225280
Webcast: http://public.viavid.com/index.php?id=129164
Replays, Available through May 29, 2018:
Domestic: 844-512-2921
International: 412-317-6671
Replay PIN: 9225280
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® (currently pending FDA clearance) in 2013 as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.
CONTACTS:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
[email protected]
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
[email protected]
